1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Orexo AB (publ)

Orexo AB (publ)

ORXOF
Orexo AB (publ)US flagOther OTC
2.10
USD
- -
- -
73.77MMarket Cap
Orexo AB (publ)
ORXOF
(Other OTC)

Recent

price

2.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.99
7.35
11.08
14.3
17.46
18.74
20.47
18.64
22.66
24.4
19.29
16.46
18.17
18.56
0.86
0.75
3.63
Revenue per Share
-3.81
-14.43
-2.92
-5.16
-1.73
-6.09
0.84
0.67
3.99
6.33
-2.45
-6.51
-5.17
-3.73
-5.89
18.46
15.81
Basic EPS, GAAP
-1.98
-4.49
0.78
-12.35
-14.92
-3.28
4.49
4.2
6.9
7.37
-5.03
-8.21
-5.25
-3.32
-9.6
-5.64
-1.66
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-26.91
-37.52
-39.32
-43.7
-41.57
-45.44
-44.62
-43.87
-39.85
-33.45
-36.12
-42.72
-47.85
-51.49
-57.26
-38.9
- -
Book Value per Share
2.6
5.9
1.91
-1.11
6.39
3.32
4.99
6.02
10.77
17.11
8.89
2.94
-0.68
-3.32
-4.44
14.16
10.45
Tangible Book Value per Share
23
27
29
30
33
34
34
35
35
35
34
34
34
34
34
35
35
Basic Weighted Avg Shares
210
200
326
429
570
646
706
644
783
845
664
565
624
639
30
26
126
Sales/Revenue/Turnover
-42.53
-196.13
-24.34
-32.53
-4.38
-27.95
-3.47
3.01
9.87
26.12
-5.68
-39.81
-34.31
-16.97
-1,457.91
-1,310
-157.79
Operating Margin (%)
34
279
17
51
13
81
25
21
21
41
39
53
69
77
165
67
53
Depreciation Expense
-89
-392
-86
-155
-57
-210
29
23
138
219
-84
-224
-178
-128
-203
639
551
Net Income, GAAP
- -
- -
- -
- -
- -
- -
18.26
21.89
- -
3.86
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-42.4
-196.38
-26.32
-36.09
-9.92
-32.5
4.11
3.6
17.61
25.94
-12.72
-39.56
-28.45
-20.08
-683.5
2,458.85
435.65
Profit Margin (%)
124
238
124
47
678
571
516
478
576
760
230
485
350
196
215
850
241
Working Capital
94
115
114
104
494
494
398
319
321
323
47
530
519
453
466
484
3
LT Debt
468
311
191
161
468
270
310
329
476
706
558
350
194
59
-126
491
365
Total Equity
- -
- -
- -
- -
- -
- -
-2.71
2.22
- -
22.88
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-4.3
-3.45
- -
-25.43
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
8
4
LT Borrowings
- -
483
- -
LT Finance Leases
- -
1
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
947
1,034
759

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,165
476
Cash, Cash Equivalents & STI
- -
912
386
Accounts Receivable, Net
- -
185
17
Inventories
- -
- -
- -
Total Current Liabilities
- -
315
235
Payables & Accruals
- -
- -
- -
ST Debt
- -
8
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-86.14%
-190.89%
-488.44%
Free Cash Flow
-20.02%
27.86%
-41%
Net Income, GAAP
4.07%
-48.04%
-414.93%
Sales/Revenue/Turnover
-10.13%
-21.97%
-12.46%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
139
154
136
8
30
2025
13
118
- -
3
26
2026
5
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.26
-1.04
-1.21
-3.37
-5.89
2025
-0.46
-1.15
- -
20.88
18.46
2026
-3.81
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Walvax Biotechnology Co., Ltd. (300142.SZ)
China Infrastructure Construction Corp. (CHNC)
Charlotte's Web Holdings, Inc. (CWEB.TO)
Discover Wellness Solutions Inc. (WLNSF)
Digital Commodities Inc. (DGCMF)
Alembic Pharmaceuticals Limited (APLLTD.NS)
Business
Orexo AB (publ) Orexo AB (publ) is a commercial-stage specialty pharmaceutical company that develops and commercializes improved pharmaceuticals and digital therapies addressing unmet needs in opioid use disorder, substance abuse, and mental health using proprietary drug delivery technologies including the AmorphOX powder-based platform; core products comprise Zubsolv (buprenorphine/naloxone sublingual tablet) and Izipry (high-dose naloxone intranasal powder) for opioid use disorder treatment and overdose reversal in the US, alongside digital mental health programs, with partner-led commercialization of other therapies globally. Founded in 1995 and headquartered in Uppsala, Sweden, the company maintains an international footprint with operations in the United States via its wholly owned subsidiary Orexo US, Inc. in Morristown, New Jersey, and collaborations worldwide targeting patients, caregivers, healthcare professionals, and first responders. In September 2025, Orexo US secured USD 8 million initial funding from the US Biomedical Advanced Research and Development Authority (BARDA) under a potential USD 50.9 million contract to advance OX390, an investigational intranasal AmorphOX-based rescue medication for adulterated opioid overdose-induced respiratory depression.

Company News

APIChatGPT

  • seekingalpha.com

    Orexo AB (publ) (ORXOY) Q1 2026 Earnings Call Transcript